Maximilian Bazaz-Al

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Journal: Transplantation and cellular therapy

Published: June 21, 2026

Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort.

Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 05, 2026

A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.

A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.

Journal: Blood cancer journal

Published: April 27, 2026

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.

Journal: Annals of hematology

Published: February 18, 2026

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Journal: American journal of hematology

Published: December 02, 2025

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal

Published: November 01, 2025

Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.

Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.

Journal: Haematologica

Published: June 03, 2025

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal

Published: March 11, 2025

Acute Lymphoblastic Leukemia Characterized by Rare BCR::FGFR1 Translocation: A Case Report With Literature Review.

Acute Lymphoblastic Leukemia Characterized by Rare BCR::FGFR1 Translocation: A Case Report With Literature Review.

Journal: Case reports in hematology

Published: February 24, 2025

Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.

Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.

Journal: Biomedicines

Published: December 07, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026